Loading…
AC Immune SA is projected to rise to $2.19 by 2027, a 0% move from its current price of $2.19. ACIU is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $2.12 | $2.19 | $2.26 | -0.01% |
| Aug 4 | $2.09 | $2.19 | $2.29 | -0.02% |
| Aug 5 | $2.07 | $2.19 | $2.32 | -0.02% |
| Aug 6 | $2.05 | $2.19 | $2.34 | -0.03% |
| Aug 7 | $2.03 | $2.19 | $2.36 | -0.04% |
| Aug 8 | $2.02 | $2.19 | $2.37 | -0.05% |
| Aug 9 | $2.01 | $2.19 | $2.39 | -0.06% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.01 | $2.19 | $2.39 | -0.06% |
| Week 2 | $1.93 | $2.19 | $2.47 | -0.11% |
| Week 3 | $1.88 | $2.19 | $2.54 | -0.17% |
| Week 4 | $1.84 | $2.19 | $2.60 | -0.22% |
| Week 5 | $1.80 | $2.18 | $2.65 | -0.28% |
| Week 6 | $1.76 | $2.18 | $2.70 | -0.33% |
| Week 7 | $1.73 | $2.18 | $2.75 | -0.38% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
AC Immune SA is a clinical stage biopharmaceutical company that discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules that selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
The company develops therapies such as Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease progression, and Semorinemab, an investigational monoclonal anti-Tau antibody designed to bind Tau and slow its spread between neurons for the treatment of AD. It also pursues other programs including ACI-24.060 for Down syndrome-related AD, ACI-7104.056 to treat Parkinson’s disease, and ACI-35.030 to stimulate a patient’s immune system to produce antibodies against pathological phosphorylated Tau. In addition, AC Immune advances diagnostic programs like PI-2620 for Tau in AD and non-AD Tauopathies, as well as ACI-12589 and ACI-15916, a-sync PET tracers for differential diagnosis of multiple system atrophy.
The company also researches Morphomer Tau aggregation inhibitors, Morphomer a-syn, and NeuroOrphan Tauopathies, along with discovery and preclinical molecules targeting a range of neurodegenerative diseases. AC Immune has license agreements and collaborations with Genentech, Janssen Pharmaceuticals, Life Molecular Imaging SA, and Eli Lilly and Company. Incorporated in 2003, it is headquartered in Lausanne, Switzerland.
AC Immune SA trades under the symbol ACIU and operates in the Healthcare sector. Its current price is $2.19 with a market capitalization of $222.88M and a rank of 3691. The asset sits in a micro-cap space within healthcare and shows a near-term price path that is largely around the current level, with a longer horizon that envisions a higher price path.
The 30-day forecast snapshot presents modest near-term movement, while the multi-year forecast outlines a rising trajectory into the 2030s and beyond, with notable upside by 2040 and 2050. The outlook anchors around a price range around the current price through 2026 and then expands meaningfully in later years, reflecting higher anticipated averages and potential upside in the max values across the horizon.
A major floor 14.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.5% away) — a key level to hold.
The nearest ceiling, 21.5% above — a clean break opens room to run.
A major ceiling 55.3% above — clearing it would confirm fresh momentum.
Key ACIU support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ACIU market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.29 | Sell | $2.27 | Sell |
| MA 10 | $2.27 | Sell | $2.29 | Sell |
| MA 20 | $2.34 | Sell | $2.33 | Sell |
| MA 50 | $2.43 | Sell | $2.45 | Sell |
| MA 100 | $2.70 | Sell | $2.61 | Sell |
| MA 200 | $2.91 | Sell | $2.71 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.22 | Neutral |
| Stoch RSI (14) | 31.49 | Neutral |
| CCI (20) | -98.88 | Neutral |
| Williams %R (14) | -95.65 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -7.20 | Sell |
| Bollinger %B (20,2) | 0.18 | Neutral |
| Stochastic %K (14) | 4.35 | Buy |
| TRIX (15) | -0.34 | Sell |
| Awesome (5,34) | -0.10 | Sell |
| Ultimate (7,14,28) | 39.77 | Neutral |
| Momentum (10) | -0.01 | Sell |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 2.30 | Sell |
| ADX (14) | 12.75 | Neutral |
| ATR (14) | 0.07 | Info |
Technical sentiment is NEUTRAL. The RSI14 is 40, signaling room to move but no overbought condition. The 50-day simple moving average (SMA50) stands at $2.43 and the 200-day simple moving average (SMA200) at $2.91, placing the price below both moving averages in the near term.
Support is at $2.18 and resistance at $2.66, with a 30-day range low of $1.76 and high of $2.72. Annualized volatility sits at 60%, underscoring elevated risk and swing potential in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.12 | $2.19 | $2.55 | 0% | Neutral | |
| $1.71 | $2.19 | $2.98 | 0% | Neutral | |
| $1.61 | $2.13 | $3.03 | -3% | Neutral | |
| $1.58 | $2.15 | $3.16 | -2% | Neutral | |
| $1.72 | $2.40 | $3.62 | +9% | Neutral | |
| $1.90 | $2.72 | $4.21 | +24% | Bullish | |
| $2.19 | $3.20 | $5.06 | +46% | Bullish | |
| $2.24 | $3.34 | $5.39 | +52% | Bullish | |
| $2.09 | $3.18 | $5.23 | +45% | Bullish | |
| $2.08 | $3.22 | $5.39 | +47% | Bullish | |
| $3.01 | $5.09 | $9.13 | +132% | Bullish | |
| $3.64 | $7.16 | $14.23 | +227% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.12 | $2.19 | $2.58 | +0.00% |
| September 2026 | $1.80 | $2.14 | $2.63 | -2.29% |
| October 2026 | $1.81 | $2.17 | $2.70 | +1.62% |
| November 2026 | $1.74 | $2.10 | $2.64 | -3.28% |
| December 2026 | $1.66 | $2.01 | $2.55 | -4.19% |
Click any year to see its month-by-month ACIU forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
AC Immune SA's 2026 outlook centres on $2.19, within a $2.12 to $2.55 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, ACIU could reach as high as $2.98, with a base case around $2.19 and support toward $1.71 — roughly 0% from $2.19. Price action looks broadly range-bound.
Expect ACIU to range from $1.61 to $3.03 through 2028. The $2.13 average target implies a -3% move from current prices. That is -3% versus the projected 2027 average. A consolidation phase looks the most probable path here.
The ACIU price prediction for 2029 points to an average of $2.15 (low $1.58, high $3.16) — a potential decline of -2% on today's $2.19. Price action looks broadly range-bound.
In 2030, ACIU is projected to trade between $1.72 and $3.62, averaging $2.40 — a potential gain of +9% from today's $2.19. That is up +12% on the projected 2029 average. A consolidation phase looks the most probable path here.
AC Immune SA's 2031 outlook centres on $2.72, within a $1.90 to $4.21 range. That is up +13% on the projected 2030 average. That marks a +24% change versus current levels. Momentum favours further upside here.
By 2032, ACIU could reach as high as $5.06, with a base case around $3.20 and support toward $2.19 — roughly +46% from $2.19. Buyers look set to stay in control over this stretch.
Expect ACIU to range from $2.24 to $5.39 through 2033. The $3.34 average target implies a +52% move from current prices. That is up +4% on the projected 2032 average. Momentum favours further upside here.
The ACIU price prediction for 2034 points to an average of $3.18 (low $2.09, high $5.23) — a potential gain of +45% on today's $2.19. Buyers look set to stay in control over this stretch.
In 2035, ACIU is projected to trade between $2.08 and $5.39, averaging $3.22 — a potential gain of +47% from today's $2.19. That is up +1% on the projected 2034 average. Momentum favours further upside here.
AC Immune SA's 2040 outlook centres on $5.09, within a $3.01 to $9.13 range. That is up +58% on the projected 2035 average. That marks a +132% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, ACIU could reach as high as $14.23, with a base case around $7.16 and support toward $3.64 — roughly +227% from $2.19. Momentum favours further upside here.
Investing $1,000 in ACIU today (≈ 456.621005 ACIU) could be worth
$3,271.56
+$2,271.56 (+227%) by 2050 · US Dollar
Based on the average projected ACIU price of $7.16 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ACIUwould be worth at today's price.
$1,000 invested in ACIU on Jul 31, 2025 (≈ 462.962945 ACIU) would be worth
$1,013.89
+$13.89 (+1.4%) today · 1.01× · US Dollar
Based on a ACIU entry price of $2.16 vs. today's $2.19.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.23 | $982.06 | -1.8% |
| 1 month ago | $2.38 | $920.17 | -8.0% |
| 3 months ago | $2.98 | $734.9 | -26.5% |
| 6 months ago | $3.27 | $669.72 | -33.0% |
| 1 year ago | $2.16 | $1,013.89 | +1.4% |
| All time (5.0y) ago | $7.13 | $307.15 | -69.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ACIU forecast.
Our base-case forecast reaches $4.40 around 2040.
Implied market cap at $4.40: $447.8M
The multi-year forecast shows a path toward higher values after a cautious start. For 2030, the min is $1.72, the avg is $2.40, the max is $3.62, with an ROI of 9.5% and a NEUTRAL sentiment. The 2040 forecast is more bullish, with an average of $5.09, a max of $9.13, a min of $3.01, and an ROI of 132.2%.
By 2050, the forecast envisions an average of $7.16, a max of $14.23, a min of $3.64, and an ROI of 227.2%, with a BULLISH sentiment. Earlier years from 2031 to 2035 show a transition to a BULLISH outlook, with 2031 avg $2.72 and 2032 avg $3.20, 2033 avg $3.34, 2034 avg $3.18, and 2035 avg $3.22, all labeled BULLISH. These results illustrate a long-range uptrend despite near-term caution and imply substantial upside if the higher-end outcomes materialize.
Note that these figures are estimates and not guarantees, and reflect higher volatility given the 60% annualized volatility level.
Tap a question to reveal the answer.
The 2030 forecast shows min $1.72, avg $2.40, max $3.62 with an ROI of 9.5% and a NEUTRAL sentiment.
Near term (2026–2029) is NEUTRAL, with the price around the current level. From 2031 onward, the outlook turns BULLISH, and longer-term estimates show substantial upside, including 2040 avg $5.09 (ROI 132.2%) and 2050 avg $7.16 (ROI 227.2%). These are estimates, not guarantees.
According to the forecast, the 2040 max is $9.13 and the 2050 max is $14.23. Reaching $10 is possible by 2050, but not by 2040 based on the provided max values.
Current price is $2.19 and market cap is $222.88M.
The 30-day picture is NEUTRAL with RSI14 at 40. SMA50 is $2.43 and SMA200 is $2.91. Support is at $2.18, resistance at $2.66, and the 30-day range spans from $1.76 to $2.72, with an annualized volatility of 60%.
AC Immune SA Community Discussion
0Share your AC Immune SA price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.